As the curtain came down on a quarter many in biotech would rather forget, big pharma groups stood out by being the least bad investment option.
Grifols has announced intriguing results in a subgroup of patients in a large Alzheimer's disease study, Ambar, but the finding could also benefit other suppliers of…
A damning report by the US pricing watchdog Icer could bode ill for the uptake of Shire’s big hereditary angioedema hope.
Several large-cap drug stocks registered healthy gains across the third quarter of 2018, signalling investors' growing confidence in biopharma after a disappointing…
A US complete response letter leaves Ruconest at the mercy of rivals like Shire.
Shire's big pipeline hope, lanadelumab, should get approved soon – but will sales live up to expectations?
Roche's Hemlibra has impressed, but uptake might not be as fast as some hope.
The US government is trying to change the way Medicare reimburses doctors for office-administered drugs – but whether it will succeed is another story.